Challenges in the inclusion of patients with neuroendocrine and endocrine neoplasms in clinical trials (CTs): How to minimize screening failures (SF)

#3498

Introduction: Study coordinators working in a Clinical Trials Unit (CTU) are essential for the optimal development of CTs in oncology. Patients with neuroendocrine neoplasms (NENs) treated in CTs have specific challenges related to the heterogeneity of the disease, making their inclusion and screening process more complex.

Aim(s): In the present work, we analyse reasons for SF in patients with NENs and endocrine tumors included in CTs.

Materials and methods: All active interventional CTs opened in our institution between 2015 and 2021 were reviewed by the CTU. Studies including patients with NENs and endocrine tumors were considered for analysis. Number and reasons for SF were collected.

Conference:

Presenting Author:

Authors: Perera J, Caparrós J, Hernando J, Garcia A, Esteban-Villarrubia J,

Keywords: Clinical trials unit, neuroendocrine neoplasm, Study coordinators, Screening failure, endocrine tumor, VHIO, Oncology, NET,